Madrigal Pharmaceuticals, Inc. Earnings

Madrigal Pharmaceuticals, Inc.’s revenue jumped 210.77% since last year same period to $321.08Mn in the Q4 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 11.77% jump in its revenue since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit jumped 1.42% since last year same period to $-58.58Mn in the Q4 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 48.7% jump in its net profits since last 3-months.

Madrigal Pharmaceuticals, Inc.’s net profit margin jumped 68.28% since last year same period to -18.24% in the Q4 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 54.11% jump in its net profit margins since last 3-months.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.89 - a -47.43% fall from last quarter’s estimates.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.89.

Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.